TempraMed Technologies (FRA:9DY) ROCE %: 0.00% (As of Mar. 2026)


FRA:9DY TempraMed Technologies Ltd FRA:9DY
10 GF Score
Price €0.33
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies ROCE %?

TempraMed Technologies FRA:9DY -18.63% 10 ROCE % is 0.00% as of Mar. 2026. GuruFocus rates FRA:9DY with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TempraMed Technologies's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.00%.

TempraMed Technologies  (FRA:9DY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TempraMed Technologies ROCE % Related Terms

TempraMed Technologies ROCE % Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies ROCE % Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
0.00 0.00 0.00

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:9DY
10GF Score
TempraMed Technologies Ltd FRA:9DY
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies ROCE % Calculation

TempraMed Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-15.112/( ( (0.448 - 3.366) + (1.573 - 2.565) )/ 2 )
=-15.112/( (-2.918+-0.992)/ 2 )
=-15.112/-1.955
=772.99 %

TempraMed Technologies's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-8.636/( ( (1.573 - 2.565) + (1.254 - 2.113) )/ 2 )
=-8.636/( ( -0.992 + -0.859 )/ 2 )
=-8.636/-0.9255
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
TempraMed Technologies (FRA:9DY) has a ROCE % of 0.00% as of Mar. 2026.
Is TempraMed Technologies' ROCE % too high?
TempraMed Technologies' current ROCE % is 0.00%. Overall, TempraMed Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' ROCE % compare to ABT and SYK?
TempraMed Technologies' ROCE % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TempraMed Technologies's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. TempraMed Technologies' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current ROCE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
10GF Score

Get the complete analysis for FRA:9DY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price